Immunic presents new CALIPER trial data showing reduced MS brain lesions
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
Immunic Inc presented new data from its Phase 2 CALIPER trial in progressive multiple sclerosis at the ACTRIMS Forum in San Diego in February 2026. The company's chief medical officer discussed findings showing Vidofludimus calcium reduced both acute and chronic inflammatory brain lesions.
The CALIPER trial, which was initially read out in mid-2023, enrolled patients with progressive MS. Two posters presented at the conference focused on MRI outcomes and effects on Epstein-Barr virus (EBV) reactivation.
The MRI outcomes poster showed that Vidofludimus calcium had a reducing effect on both gadolinium-enhancing and T2 lesions, which are markers of acute inflammatory disease driven by peripheral immune cells entering the brain. The trial also found a statistically significant reduction in slowly expanding lesions (SELs) for the 45mg dose of Vidofludimus calcium compared to placebo. SELs are markers of chronic compartmentalized inflammation inside the brain, a component of MS that is not yet fully understood and is not well detected by standard MRI measures.
The second poster examined effects on EBV-specific T cell receptor repertoires. About three years ago, a publication clearly showed that EBV is a necessary condition for MS. The virus is a chronic infection that most people acquire early in life and remains dormant in immune cells like B cells. There is growing evidence that molecular mimicry may play a role, where antibodies reacting to EBV might also attack the central nervous system.
Vidofludimus calcium is a broad-spectrum antiviral drug. In the CALIPER trial, the company showed clinical evidence of reduced EBV reactivation compared to placebo for the first time. T-cell receptor repertoire analysis showed that under treatment with Vidofludimus calcium, EBV antigens dropped in ranking, indicating fewer reactivations.
Immunic is approaching the readout of two identical Phase 3 trials in relapsing MS at the end of 2026, each enrolling over 1,100 patients — more than 3,000 individuals across the program. These results will support potential regulatory submissions and, possibly, product launch.